Generation Bio Co. (GBIO)
Generation Bio Statistics
Share Statistics
Generation Bio has 67.01M shares outstanding. The number of shares has increased by 0.72% in one year.
Shares Outstanding | 67.01M |
Shares Change (YoY) | 0.72% |
Shares Change (QoQ) | 0.32% |
Owned by Institutions (%) | 80.69% |
Shares Floating | 45.81M |
Failed to Deliver (FTD) Shares | 9.55K |
FTD / Avg. Volume | 2% |
Short Selling Information
The latest short interest is 1.69M, so 2.52% of the outstanding shares have been sold short.
Short Interest | 1.69M |
Short % of Shares Out | 2.52% |
Short % of Float | 4.2% |
Short Ratio (days to cover) | 3.82 |
Valuation Ratios
The PE ratio is -0.54 and the forward PE ratio is -0.41. Generation Bio's PEG ratio is -0.53.
PE Ratio | -0.54 |
Forward PE | -0.41 |
PS Ratio | 3.55 |
Forward PS | 0.3 |
PB Ratio | 0.82 |
P/FCF Ratio | -0.78 |
PEG Ratio | -0.53 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Generation Bio.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.5, with a Debt / Equity ratio of 1.09.
Current Ratio | 5.5 |
Quick Ratio | 5.5 |
Debt / Equity | 1.09 |
Debt / EBITDA | -1.26 |
Debt / FCF | -1.03 |
Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | $172.97K |
Profits Per Employee | $-1.14M |
Employee Count | 115 |
Asset Turnover | 0.09 |
Inventory Turnover | n/a |
Taxes
Income Tax | 0 |
Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -85.61% in the last 52 weeks. The beta is 2.78, so Generation Bio's price volatility has been higher than the market average.
Beta | 2.78 |
52-Week Price Change | -85.61% |
50-Day Moving Average | 0.51 |
200-Day Moving Average | 1.64 |
Relative Strength Index (RSI) | 43.6 |
Average Volume (20 Days) | 478.15K |
Income Statement
In the last 12 months, Generation Bio had revenue of 19.89M and earned -131.67M in profits. Earnings per share was -1.98.
Revenue | 19.89M |
Gross Profit | 19.89M |
Operating Income | -142.39M |
Net Income | -131.67M |
EBITDA | -74.26M |
EBIT | -79.19M |
Earnings Per Share (EPS) | -1.98 |
Balance Sheet
The company has 76.3M in cash and 93.56M in debt, giving a net cash position of -17.26M.
Cash & Cash Equivalents | 76.3M |
Total Debt | 93.56M |
Net Cash | -17.26M |
Retained Earnings | -703.04M |
Total Assets | 231.2M |
Working Capital | 157.85M |
Cash Flow
In the last 12 months, operating cash flow was -88.56M and capital expenditures -2.4M, giving a free cash flow of -90.96M.
Operating Cash Flow | -88.56M |
Capital Expenditures | -2.4M |
Free Cash Flow | -90.96M |
FCF Per Share | -1.37 |
Margins
Gross margin is 100%, with operating and profit margins of -715.82% and -661.91%.
Gross Margin | 100% |
Operating Margin | -715.82% |
Pretax Margin | -661.91% |
Profit Margin | -661.91% |
EBITDA Margin | -373.33% |
EBIT Margin | -715.82% |
FCF Margin | -457.29% |
Dividends & Yields
GBIO does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | n/a |
FCF Yield | n/a |
Analyst Forecast
The average price target for GBIO is $8, which is 1900% higher than the current price. The consensus rating is "Buy".
Price Target | $8 |
Price Target Difference | 1900% |
Analyst Consensus | Buy |
Analyst Count | 4 |
Scores
Altman Z-Score | -4.37 |
Piotroski F-Score | 3 |